Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from enVVeno Medical ( (NVNO) ).
On February 4, 2026, enVVeno Medical announced that it had regained compliance with Nasdaq’s minimum bid price requirement, after its common stock closed at or above $1.00 for 10 consecutive business days from January 20 to February 2, 2026, restoring its standing for continued listing on the exchange. The company reported approximately $28 million in cash and investments as of December 31, 2025, and said that the combination of this financial position and its restored Nasdaq compliance supports its ongoing execution of 2026 strategic plans, potentially strengthening its operational footing and visibility with investors.
The most recent analyst rating on (NVNO) stock is a Hold with a $11.50 price target. To see the full list of analyst forecasts on enVVeno Medical stock, see the NVNO Stock Forecast page.
Spark’s Take on NVNO Stock
According to Spark, TipRanks’ AI Analyst, NVNO is a Neutral.
The score is primarily pressured by weak financial performance (no revenue, sizable losses, and ongoing cash burn) and a negative FDA-related setback. Technicals also reflect a weak longer-term trend with negative MACD. Low debt provides some balance-sheet support, but valuation support is limited given a negative P/E and no dividend yield.
To see Spark’s full report on NVNO stock, click here.
More about enVVeno Medical
enVVeno Medical Corporation (NASDAQ: NVNO) is an Irvine, California-based, late clinical-stage medical device company focused on developing innovative bioprosthetic, tissue-based solutions to improve the standard of care for patients with deep venous disease.
Average Trading Volume: 22,099
Technical Sentiment Signal: Sell
Current Market Cap: $7.28M
See more data about NVNO stock on TipRanks’ Stock Analysis page.